Cynapsus Therapeutics Inc.
Description Cynapsus Therapeutics Inc., a specialty pharmaceutical company, engages in developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinsons disease. Its lead drug candidate includes APL-130277, an easy-to-administer, fast-acting, and oral reformulation of an approved drug, such as apomorphine, an injection that is used to rescue patients from OFF episodes. The companys drug would treats patients with moderate to severe Parkinsons disease and address unmet clinical need as expressed by clinicians and patients. The company was formerly known as Cannasat Therapeutics Inc. and changed its name to Cynapsus Therapeutics Inc. in April 2010. Cynapsus Therapeutics Inc. is headquartered in Toronto, Canada. To view the detailed information, you need to SUBSCRIBE with us. |
 |